Event Participants

Management Team:

  • Ms. Ameera Shah – Chairperson & Whole-Time Director
  • Mr. Surendran Chemmenkotil – Managing Director
  • Mr. Sameer Patel – Chief Financial Officer
  • Mr. Mohan Menon – Chief Marketing Officer
  • Mr. Pinakin Shah – Chief Information Officer
  • Dr. Nilanju Sarma – Head of Research & Development and Academics
  • Other members of the leadership team

Business Overview & Historical Context

Metropolis Healthcare started as Dr. Sushil Shah's lab and has grown over 25 years from a single lab to a multi-center chain with:

  • 209 laboratories across India and 5 international markets
  • 5,000+ collection centers
  • Operations in 750 towns in India
  • Presence in 5 international countries (Kenya, Zambia, Ghana, Uganda, Tanzania) with 24 labs
  • FY26 revenue: INR 1,646 crores
  • Regional revenue contribution: West 50%, South 27%, North 18%, East 5%
  • Business mix: 57% B2C (patient-facing), 43% B2B (institutional)
  • 4,500+ varieties of tests offered
  • 30,000+ prescribing specialists (gastroenterologists, neurologists, gynecologists, oncologists)
  • 6,000+ employees

Financial Performance

Historical Growth (3-year CAGR):

  • Revenue: 17.6% (FY26: 23.6%)
  • EBITDA: 18.6% (FY26: 23%)
  • PAT: Similar growth pattern to revenue and EBITDA
  • FY26 EBITDA margin: 24.4% (organic margin 25.9% excluding Core Diagnostics acquisition impact)

Margin Context:

The Core Diagnostics acquisition (breakeven at acquisition) suppressed overall margin by 1.5%. The company expects this gap to narrow as Core moves into profitability, targeting 20-25% margins in 3-4 years.

Growth Drivers:

  • Volume-led growth (not price-led)
  • Annual price increases of 2-3%
  • Revenue per patient increase from product mix change
  • Productivity per employee up 15% in FY26

Industry Context & Market Opportunity

  • Current Indian diagnostics market: $11 billion
  • Expected to grow to $28.5 billion in 8 years at 11% CAGR
  • Less than 6% of Indians have been diagnosed, indicating significant growth potential
  • 60% of mortality comes from non-communicable diseases (cholesterol, diabetes, heart issues)
  • Fastest growing therapeutic areas: oncology (cancers) and neurological diseases
  • Market organizing gradually from unorganized to organized sector

Competitive Advantages & Moat

Quality Differentiation:

  • 99.99% EQAS score (top 1% of labs globally)
  • CAP (College of American Pathologists) accredited since 2005
  • Monthly blind sample testing for quality validation
  • 149-step process for even simple tests like blood sugar

Scientific Capabilities:

  • Largest test menu in industry (4,500 tests)
  • 42% of business from specialty testing
  • Added 380 specialty tests in last year
  • Medical advisory board of 60 experts
  • Molecular pathologists and bioinformaticians
  • Two CAP-accredited genomics labs (West and North)

Operational Excellence:

  • Culture of treating every sample like "your own mother's sample"
  • Highest NPS scores in industry
  • Integrated international operations (30-40% of international samples processed in India)

Growth Strategy & Initiatives

Five Growth Engines:

1. Network Expansion: Current lab-to-center ratio 1:24, target 1:35. Plan to add 250-300 centers every quarter

2. TruHealth: Wellness bundles contributing 20% of revenue, target 25%. Adding adjacent services (radiology, doctor consultation, diet consulting)

3. Specialty Testing: 42% of business, target disproportionate growth. Added 400 tests in last 15 months

4. Digital Channels: 25% of business from digital platforms. Lower acquisition cost and 2x LTV compared to offline channels

5. Inorganic Growth: History of 25+ successful acquisitions. Core Diagnostics turnaround from breakeven to high single-digit EBITDA in one year

Specific Initiatives:

  • 100 Mini-Hubs: Plan to create 100 centers offering basic radiology (X-ray, ultrasound, 2D echo). 50 existing centers to be upgraded, 15 new centers to be established
  • Real Estate Utilization: Utilize 700+ owned centers beyond current 6:30 AM-10:30 AM peak hours for adjacent healthcare services
  • TruHealth Enhancements: Launching diet consultation based on blood work, obesity management programs, vital check-ups
  • Genomics Growth: 2x growth in genomics in last year. NovaSeq™ X System technology. Added medical geneticists and genetic counselors
  • International Business: Operations in 5 countries (Kenya, Zambia, Ghana, Uganda, Tanzania). Leadership position in Kenya and Zambia. Top 3 in other markets. Self-funded without capital from India

Technology Transformation

Digital Capabilities:

  • Post-COVID digitization and automation of processes
  • Web and app platforms for customer acquisition
  • Home visit apps for sample collection
  • Partner portals for B2B clients

AI Initiatives:

  • Report summarization using AI
  • Diet guidance algorithms
  • "Talk to an Expert" feature for clinician connectivity
  • Disease trend analysis for doctors
  • Customer service automation to reduce resolution time by 50%

Future Plans:

  • Building in-house technology team
  • Faster project execution capabilities
  • Enhanced customer and partner experiences

Financial Targets & Guidance

Medium-term Guidance:

  • Revenue growth: 14-15% (without price increases)
  • Q1 FY27 growth: 17% achieved
  • North India: fastest growing region in Q1

Margin Improvement:

  • Target EBITDA margin: 27-28% (from current 24.4%)
  • Drivers: Better mix towards specialty and genomics, digitalization, automation, network utilization

Capital Efficiency:

  • Target working capital: single digit (from current double digit)
  • Discipline capital allocation
  • Regular dividend payouts (22% of PAT in FY26)
  • Bonus issue: 3:1 completed

Regional Performance

  • North India: Contribution increased from 7-8% to 18% in one year. Fastest growing region in Q1 FY27
  • East India: 5% contribution. Requires more investment for growth
  • International: <10% revenue contribution. Self-sustaining operations

Corporate Governance & Ownership

  • Promoter holding: Not quantified in transcript
  • Institutional holding: Diversified cap table
  • No private equity overhang
  • Professional management team with promoter leadership
  • Strong compliance focus prioritizing compliance over other considerations

Forward-looking Commentary

Growth Opportunities:

  • Tier 2 and Tier 3 towns showing strong growth potential
  • Hospital expansion into smaller towns driving specialty test demand
  • Corporate health check opportunity from government mandate for employees over 45 years
  • Insta60 service (60-minute home collection) expanding to more cities

Strategic Direction:

  • Focus on volume-led growth rather than margin maximization
  • Periodic reinvestment cycles for long-term relevance
  • Goal to become number one diagnostics player in India
  • Exploration of adjacent healthcare services beyond diagnostics

Risk Factors Mentioned

  • Industry competition from health tech players, pharma companies entering diagnostics
  • Need for continuous innovation and reinvestment
  • Market dynamics including CGHS price impacts (not material for Metropolis)